Basal Cell Carcinoma Recurrence After Mohs Surgery
Basal cell carcinoma (BCC) is the most common skin cancer in the US and can cause significant adverse effects.
Mohs micrographic surgery, the treatment of choice for higher risk BCC, allows for removal of lesions with preservation of healthy tissue. Although the BCC recurrence rate post Mohs surgery is estimated at 1-2%, recent data is lacking to validate this historical measurement.
Our purpose is to determine the current recurrence rate of BCC after Mohs surgery.
Basal Cell Carcinoma
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Basal Cell Carcinoma Recurrence|
- Recurrence of BCC [ Time Frame: either after 1 study visit (historical arm), or 3 years (prospective arm) ]
- Risk Factors for recurrence of BCC [ Time Frame: either after 1 study visit (historical arm), or 3 years (prospective arm) ]
|Study Start Date:||May 2008|
|Study Completion Date:||May 2009|
|Primary Completion Date:||May 2009 (Final data collection date for primary outcome measure)|
266 cases of BCC treated with Mohs surgery approximately 2-5 years ago will be assessed for recurrence.
300 cases of BCC will be followed annually for 3 years after Mohs surgery to assess for recurrence.
Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer in the United States, affecting nearly one million of all Americans. While BCC is rarely mortal, it has significant associated physical, psychological, and monetary costs to patients such as disfigurement and sensory loss. Individuals who have been diagnosed with at least one BCC lesion are likely to be diagnosed with more in the future. Treatment of these lesions and recurrent physician appointments can be a great inconvenience to patients, resulting in expenses to patients and loss of work and family time.
The Mohs surgery technique is associated with a low recurrence rate for BCC and is preferred for higher risk tumors and for tumors in cosmetically sensitive sites on the head and neck. While recurrence rates of BCC post Mohs are 1-2% for primary basal cells, recent data is not available to validate this historical assessment. Currently, comprehensive rates of recurrence are not available because a national registry of recurrence rates for BCC and squamous cell carcinoma (SCC) does not exist.
The purpose of this study is to both historically and prospectively assess current basal cell carcinoma recurrence rates in patients undergoing Mohs micrographic surgery.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00882791
|United States, Illinois|
|Northwestern University Feinberg School of Medicine, Department of Dermatology|
|Chicago, Illinois, United States, 60611|
|DuPage Medical Group Dermatology|
|Naperville, Illinois, United States, 60563|
|Principal Investigator:||Murad Alam, MD||Northwestern University|